[Ip-health] Comparison between April 29 and May 7 version of WHA 72 resolution on transparency

Claire Cassedy claire.cassedy at keionline.org
Wed May 8 07:07:21 PDT 2019


Comparison between April 29 and May 7 version of WHA 72 resolution on

Posted on May 8, 2019 by James Love

At the May 7 informal, countries from Northern Europe with strong pharma
industry lobbies proposed dozens of changes in the transparency resolution
to make it weaker and in many cases confusing and meaningless.

This table compares the two texts:

KEI’s comment on the proposed changes is as follows:

    “At a moment when the public is looking to their elected governments to
address the crisis in the pricing of new drugs and other biomedical
inventions, the World Health Organization has been asked to do something
important; improve the transparency of markets for biomedical products and
services. A resolution sent to governments by the WHO on April 29 that had
ten co-sponsors from Europe, Asia and Africa set out an ambitious but
practical agenda for making drug prices, R&D investments, patent landscapes
and clinical trial outcomes progressively more transparent, and access to
information more equal. At a May 7 negotiation on the text, a group of
Northern European countries, lead by Germany, Denmark, Sweden and the UK,
plus Australia, led an effort to gut the resolution, on behalf of drug
companies who oppose transparency. The USA, Austria, Poland and Hungary
also sought to eliminate key elements of the resolution. If the secrecy
promoting changes are accepted, the public will continue to operate with
less information about biomedical markets, and governments will have less
power to curb high prices and reform R&D incentives.” James Love, KEI

The original sponsors are: Italy, Greece, Malaysia, Portugal, Serbia,
Slovenia, South Africa, Spain, Turkey, Uganda.

The countries that proposed changes in the May 7 informal, and the number
of changes they proposed, were:

    Australia: 8
    Austria: 3
    Brazil: 9
    Denmark: 15
    Germany: 25
    Hungary: 2
    Poland: 2
    Spain: 8
    Sweden: 11
    UK: 11
    USA: 2

More information about the Ip-health mailing list